

and stroke. The primary aim of this study was to determine whether these CX3CR1 single nucleotide polymorphisms are associated with cerebrovascular disease.

We analyzed 235 unrelated Japanese patients with ischemic cerebrovascular disease (CVD) and 306 age- and sex-matched controls. All CVD patients had attended the outpatient clinic of Keio University Hospital, Tokyo for regular follow-up examinations. We selected CVD patients aged  $\leq 70$  years at the onset of CVD. On the basis of the Classification of Cerebrovascular Diseases III report from the committee established by the National Institute of Neurological Disorders and Stroke, CVD patients diagnosed with atherothrombotic infarction, lacunar infarction, or transient ischemic attack (TIA) were enrolled in this study. Those with cardioembolic cerebral infarction or cerebral hemorrhage were excluded. Controls were patients who had had regular check-ups. Those with a clinical history of cerebrovascular disease, myocardial infarction, or peripheral vascular disease were excluded. Written informed consent was obtained from all subjects after a full explanation of the study and a guarantee of total confidentiality. Brain CT and/or MRI was performed on all patients with CVD. Hypertension, hypercholesterolemia, and smoking were defined as described previously [8].

To analyze the T280M and V249I polymorphisms of CX3CR1, polymerase chain reaction (PCR) was carried out as described previously [8]. Briefly, amplification of a 307 bp fragment of the CX3CR1 gene was performed with the 5' primer 5'-GCTACTTCAGAATCATCCAG-3' and 3' primer 5'-AGGCATTTCCCATACAGGTG-3'. PCR consisted of 1 cycle of 15 min at 80 °C and 4.5 min at 94 °C, 44 cycles of 30 s at 94 °C, 45 s at 50 °C, and 1 min at 72 °C, followed by 7 min at 72 °C in a Gene Amp PCR system 2400 (Perkin-Elmer, Foster City, CA, USA). The PCR product (5  $\mu$ l) was cleaved with 20 U BsmBI restriction enzyme (New England Biolabs, Beverly, MA, USA) or with 20 U Psp1406I restriction enzyme (Takara Shuzo, Ohtu, Shiga, Japan). To analyze the T280M polymorphism, BsmBI digestion of the PCR product yielded bands of 126, 106, and 75 bp in TT homozygotes, 181 and 126 bp in MM homozygotes, and all bands in heterozygotes. For the V249I polymorphism, Psp1406I digestion of the PCR product yielded bands of 192, and 115 bp in VV homozygotes, 307 bp in II homozygotes, and all bands in heterozygotes.

The differences in genotype frequencies and other risk factors were analyzed by  $\chi^2$  test. Mean age and allele frequencies in the two groups were compared by Student's *t*-test. Multiple logistic regression methods were used to control for possible confounding factors. All statistical analyses were performed using Statview software (ver 5.0 for Windows, SAS Institute, CA, USA).

The 235 CVD patients and 306 controls were well matched in terms of age and sex (Table 1). The risk factors hypertension, diabetes mellitus, and smoking were significantly more common in CVD patients than in controls ( $p < 0.001$ ). The frequencies of the V249I and T280M poly-

Table 1  
Clinical characteristics of CVD patients and controls

	Controls	CVD patients	
	(n = 306)	(n = 235)	<i>p</i> <sup>a</sup>
Male (%)	77.5	77.9	NS <sup>b</sup>
Age, mean $\pm$ S.D., years	58.6 $\pm$ 4.3	58.3 $\pm$ 7.8	NS <sup>b</sup>
Hypertension (%)	25.1	56.2	<0.001
Hypercholesterolemia (%)	33.0	38.6	0.177
Diabetes mellitus (%)	6.54	25.8	<0.001
Smoking (%)	37.6	53.3	<0.001
Body mass index >27.3 kg/m <sup>2</sup> (%)	5.19	9.02	0.737
Family history (%)	24.2	29.3	0.298

<sup>a</sup>  $\chi^2$  test was used to compare values of all parameters in CVD patients and controls, except for age, which was compared by Student's *t*-test.

<sup>b</sup> Not significant.

morphisms showed no deviation from Hardy–Weinberg equilibrium: V249I ( $p = 0.59$ ) and T280M ( $p = 0.59$ ), respectively.

The I and M allele frequencies were not significantly different between CVD patients and controls: 4.3% versus 4.7%, odds ratio (OR) = 0.89 (95% confidence interval (CI) = 0.50–1.60,  $p = 0.70$ ) and 6.2% versus 5.2%, OR = 1.19 (95% CI = 0.71–2.00,  $p = 0.51$ ), respectively (Table 2). There was also no deviation in the frequency of carriers (II + VI and MM + TM) between CVD patients and controls: 7.7% versus 8.2%, OR = 0.93 (95% CI = 0.49–1.76,  $p = 0.83$ ) and 10.6% versus 9.5%, OR = 1.14 (95% CI = 0.65–2.00,  $p = 0.66$ ), respectively. Eight of the nine possible combined genotypes were observed in our population (Table 3). The frequency of the VV–TT combined genotype in the three groups of CVD patients, the AT, the lacunar and the TIA group, was 88.4, 86.6, and 95.8, respectively, but there was no statistic difference in the frequency between these subgroups of CVD patients and controls.

There were no carriers (II + VI) of the I allele in TIA patients with the V249I genotype. In contrast, there was no significant deviation of genotype between stroke subtypes and controls. In logistic regression analysis, sex, age, hypertension, hypercholesterolemia, diabetes mellitus, current smoking, body mass index, family history of stroke and CX3CR1 genotypes (VV versus VI + II or TT versus TM + MM) were included as independent variables. This analysis revealed that presence of the I allele or M allele was independent of these acquired risk factors.

The present study examined the relation between CVD and two CX3CR1 single nucleotide polymorphisms. There was no significant difference in T280M and V249I polymorphisms between patients with CVD and controls.

In two animal studies on atherogenesis, CX3CR1<sup>-/-</sup> Apolipoprotein E<sup>-/-</sup> (ApoE) double knockout mice given a western diet showed a reduction in macrophage infiltration in the vessel wall and decreased size of atherosclerotic lesions compared with CX3CR1<sup>+/+</sup> ApoE<sup>-/-</sup> littermates [2,10]. These results indicate that CX3CR1 may play a critical role in the first step of atherogenesis;

Table 2  
Genotype and allele frequencies of V249I and T280M polymorphisms of CX3CR1 gene in CVD patients and controls

Genotype	CVD patients (n=235)	AT (n=69)	Lacunar (n=142)	TIA (n=24)	Controls (n=306)
II + VI (%)	7.7 (18)	8.7 (6)	8.5 (12)	0.0 (0)	8.2 (25)
VV (%)	92.3 (217)	91.3 (63)	91.5 (130)	100.0 (24)	91.8 (281)
<i>p</i> <sup>a</sup>	0.828	0.886	0.920	0.145	–
MM + TM (%)	10.6 (25)	8.7 (6)	12.7 (18)	4.2 (1)	9.5 (29)
TT (%)	89.4 (210)	91.3 (63)	87.3 (124)	95.8 (23)	90.5 (277)
<i>p</i> <sup>a</sup>	0.655	0.840	0.304	0.384	–
I (%)	4.3	5.1	4.6	0.0	4.7
V (%)	95.7	94.9	95.4	100.0	95.3
<i>p</i> <sup>a</sup>	0.705	0.868	0.916	0.123	–
M (%)	6.2	5.8	7.0	2.1	5.2
T (%)	93.8	94.2	93.0	97.9	94.8
<i>p</i> <sup>a</sup>	0.506	0.788	0.280	0.336	–

Number of subjects (X).

<sup>a</sup>  $\chi^2$  tests were used to compare genotype and allele frequencies between controls and all CVD patients and between controls and individual groups of CVD patients. AT: atherothrombotic infarction, Lacunar: lacunar infarction, TIA: transient ischemic attack.

that is, interaction between vascular endothelial cells and macrophages.

In two human studies on the association between these two polymorphisms and coronary artery disease, the I allele had the capability to reduce the risk of coronary artery disease [11,12]. In contrast there was no association with peripheral artery disease of Fontaine stage IIa or greater in white healthy controls [6]. Our study failed to reveal an association between ischemic stroke and two CX3CR1 single nucleotide polymorphisms. The frequency of the two single nucleotide polymorphisms, V249I and T280M, (4.7 and 5.2%) in the Japanese population was significantly lower than that in the Caucasian population (25.7 and 13.5%, respectively) [3]. We cannot exclude the possibility that the difference in frequency of these single nucleotide polymorphisms between Caucasian and Japanese people may have influenced our results. The relevance of these polymorphisms should be investigated in other populations and by prospective and family studies. On the other hand, recent Italian study on the association between the two polymorphisms and internal carotid artery (ICA) occlusive disease showed the presence of the M280 haplotype reduced risk of ICA occlusive disease and the I249 haplotype was associated with increased stability of carotid

plaques [5]. This study, suggested the two polymorphisms were associated with extracranial atherosclerosis. The first step of atherosclerosis, the fatty streak formation, developed in intracranial arterial wall significantly later than in extracranial arterial wall in rabbits [9]. The mean age of our enrolled subjects was about 10 years younger than the mean age of the Italian study's subjects [5]. Our protocol cannot exclude contribution of extracranial atherosclerosis, i.e., artery to artery embolism, and these factors may have influenced our results. Nevertheless, our findings strongly suggest that the T280M and V249I polymorphisms in the CX3CR1 gene may have less effect on the occurrence of CVD than on coronary artery disease or ICA occlusive disease.

Our other important finding is the detection of single nucleotide polymorphisms of the CX3CR1 gene in the Japanese population, and a new haplotype, V249-M280. A previous report documented that these polymorphisms were found only in a white population, but not in Vietnamese or West Africans [3]. Therefore, the I and M alleles had been thought to be unique to Caucasians. The frequency of the combined genotype VV–TT in the Japanese population was high, 88.1 and 90.5% in CVD patients and in controls, respectively, while the other combinations appeared to have very low frequencies. These findings suggest that the V249-T280 haplotype has a high proportion of the nine possible combined genotypes in Asians, including Japanese. In addition, only six of the nine possible combined genotypes were reported in the white population [3,6,11,12], and only three haplotypes, V249-T280, I249-T280, and I249-M280, of the four possible haplotypes have been detected. In this study, we identified eight combined genotypes including VV + TM and VV + MM, demonstrating the presence of a new haplotype, V249-M280, is present in Japanese.

In conclusion, this study revealed no association between both polymorphisms in the CX3CR1 gene and ischemic cerebrovascular disease. Although further studies are needed to evaluate whether CX3CR1 may play a role in the pathogenesis of CVD, our results indicate that CX3CR1 gene polymor-

Table 3  
Combined genotype frequencies of V249I and T280M polymorphisms of CX3CR1 gene in CVD patients and controls

Combined genotype	V249I	T280M	CVD patients % (n=235)	Controls % (n=306)
1	VV	TT	88.1 (207)	90.5 (277)
2	VV	TM	4.3 (10)	1.0 (3)
3	VV	MM	0.0 (0)	0.3 (1)
4	VI	TT	1.3 (3)	0.0 (0)
5	VI	TM	4.7 (11)	6.9 (21)
6	VI	MM	0.9 (2)	0.0 (0)
7	II	TT	0.0 (0)	0.0 (0)
8	II	TM	0.0 (0)	0.7 (2)
9	II	MM	0.9 (2)	0.7 (2)

Number of subjects (X).

phisms may have less effect on the occurrence of ischemic CVD.

### Acknowledgment

This study was supported by a Grant-in-aid for scientific research No. H13-genome-006 from the Ministry of Health, Labor and Welfare of Japan.

### References

- [1] J.F. Bazan, K.B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D.R. Greaves, A. Zlotnik, T.J. Schall, A new class of membrane-bound chemokine with a CX3C motif, *Nature* 385 (1997) 640–644.
- [2] C. Combadiere, S. Potteaux, J.L. Gao, B. Esposito, S. Casanova, E.J. Lee, P. Debre, A. Tedgui, P.M. Murphy, Z. Mallat, Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice, *Circulation* 107 (2003) 1009–1013.
- [3] S. Faure, L. Meyer, D. Costagliola, C. Vaneensberghe, E. Genin, B. Autran, J.F. Delfraissy, D.H. McDermott, P.M. Murphy, P. Debre, I. Theodorou, C. Combadiere, Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1, *Science* (2000) 287.
- [4] A.M. Fong, L.A. Robinson, D.A. Steeber, T.F. Tedder, O. Yoshie, T. Imai, D.D. Patel, Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow, *J. Exp. Med.* 188 (1998) 1413–1419.
- [5] G. Giorgio, M.L. Biondi, O. Turri, E. Guagnellini, R. Scorza, Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor, *Stroke* 35 (2004) 1276–1279.
- [6] A. Gugl, W. Renner, G. Seino, M. Brodmann, E. Pabst, T.C. Wascher, B. Paulweber, B. Iglseder, E. Pilger, Two polymorphisms in the fractalkine receptor CX3CR1 are not associated with peripheral arterial disease, *Atherosclerosis* 166 (2003) 339–343.
- [7] T. Imai, K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiya, T.J. Schall, O. Yoshie, Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion, *Cell* 91 (1997) 521–530.
- [8] D. Ito, M. Murata, N. Tanahashi, H. Sato, A. Sonoda, I. Saito, K. Watanabe, Y. Fukuuchi, Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease, *Stroke* 31 (2000) 2661–2664.
- [9] K. Kanamaru, S. Waga, H. Tochio, K. Nagatani, The effect of atherosclerosis on endothelium-dependent relaxation in the aorta and intracranial arteries of rabbits, *J. Neurosurg.* 70 (1989) 793–798.
- [10] P. Lesnik, C.A. Haskell, I.F. Charo, Decreased atherosclerosis in CX3CR1<sup>-/-</sup> mice reveals a role for fractalkine in atherogenesis, *J. Clin. Invest.* 111 (2003) 333–340.
- [11] D.H. McDermott, J.P. Halcox, W.H. Schenke, M.A. Waclawiw, M.N. Merrell, N. Epstein, A.A. Quyyumi, P.M. Murphy, Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis, *Circ. Res.* 89 (2001) 401–407.
- [12] D. Moatti, S. Faure, F. Fumeron, Mel.-W. Amara, P. Seknadji, D.H. McDermott, P. Debre, M.C. Aumont, P.M. Murphy, D. de Prost, C. Combadiere, Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease, *Blood* (2001) 97.

# Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: *in vitro* expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X

Ikuko Isshiki<sup>a</sup>, Remi Favier<sup>b</sup>, Takanori Moriki<sup>c</sup>, Toshihiro Uchida<sup>d</sup>, Hiroaki Ishihara<sup>d</sup>, Patrick Van Dreden<sup>e</sup>, Mitsuru Murata<sup>a</sup> and Yasuo Ikeda<sup>a</sup>

We investigated a new family with cross-reactive material-positive factor X (FX) deficiency. The proband was an 11-year-old French girl from Sri Lanka with a tendency towards severe bleeding. The FX antigen level was 67%, although the activity with extrinsic pathway was 1 U/dl. The complete nucleotide sequences of all exons and exon/intron junctions of the patient's genomic DNA revealed a homozygous G → A substitution in exon 8, which would result in replacement of Gly366 with Ser. The proband is the first reported case of homozygote for the FX Gly366Ser mutation. Heterozygosity for Gly366Ser substitution was previously reported in a Japanese patient (FX Nagoya 2). We studied the functional consequences by expressing mutant FX Gly366Ser protein in HEK293 cells. FX Gly366Ser was secreted into the culture media at levels similar to wild-type FX; however, mutant FX activities were only 0.04, 1.05, and 0.75% of wild-type FX upon activation by the extrinsic system, the intrinsic system, and Russell's viper venom, respectively. Moreover, the activity of FX Gly366Ser was undetectable when analyzed with

chromogenic-activated FX and thrombin generation assays. These data suggest that the Gly366Ser substitution would cause a major defect in function of the FX molecule. *Blood Coagul Fibrinolysis* 16:9–16 © 2005 Lippincott Williams & Wilkins.

*Blood Coagulation and Fibrinolysis* 2005, 16:9–16

**Keywords:** cross-reactive material-positive factor X deficiency, factor X Nagoya 2, Gly366Ser factor X mutant

<sup>a</sup>Department of Internal Medicine, Division of Hematology, School of Medicine, Keio University, Tokyo, Japan, <sup>b</sup>Armand-Trousseau Children's Hospital, Paris, France, <sup>c</sup>Health Center, Keio University, Tokyo, <sup>d</sup>Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan and <sup>e</sup>Serbio Laboratories, Gennevilliers, France.

**Sponsorship:** R.F. was supported in part by the French Society of Pediatric Pathology.

Correspondence and requests for reprints to Mitsuru Murata, Department of Internal Medicine, Division of Hematology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: +81 3 5363 3785; fax: +81 3 3353 3515; e-mail: murata@sc.ito.keio.ac.jp

Received 1 May 2004 Revised 8 June 2004  
Accepted 9 August 2004

## Introduction

Factor X (FX) is a vitamin K-dependent protein that is synthesized by hepatocytes and circulates in plasma as a two-chain zymogen composed of a light chain (molecular weight, 16.2 kDa) and a heavy chain (molecular weight, 42.1 kDa) joined by a disulfide linkage [1,2]. FX is a primary target of serine proteases activated factor VII (FVIIa) and activated factor IX (FIXa). Once activated by these enzymes, activated factor X (FXa) is the main enzyme involved in conversion of prothrombin to thrombin [1].

The human FX gene (F10) is located on the terminal portion of chromosome 13 in q34 [3–5]. Human FX is highly homologous to other vitamin K-dependent coagulation factors, such as factor VII, factor IX, and protein C, and has a similar structure–function relation [6,7]. The gene consists of seven introns and eight exons [6]. Exon I encodes the signal sequence, exon II encodes the propeptide and  $\gamma$ -carboxyglutamic-acid-rich domain, exon III encodes a short stretch of aromatic amino acid, exons IV and V encode the epidermal-growth-factor-like

domains, exon VI encodes the activation peptide, and exons VII and VIII encode the catalytic domains.

FX plays a key role in the process of blood coagulation and is activated at the point of convergence of the intrinsic and extrinsic pathways. Activators of the intrinsic pathway include activated factor VIII, factor IXa,  $\text{Ca}^{2+}$ , and acidic phospholipids. The extrinsic pathway is activated by membrane-bound VIIa and tissue factor with  $\text{Ca}^{2+}$  [8]. Conversion of factor X to factor Xa involves cleavage of an alanine-isoleucine peptide bond in the heavy chain that liberates a small activation peptide of 52 amino acids. This leads to a conformational change and exposure of the active site triad of His236-Asp282-Ser379, which plays a critical role in the characteristic catalytic function of serine proteases.

In the intrinsic pathway of blood coagulation, this reaction is catalyzed by FIXa in the presence of activated factor VIII,  $\text{Ca}^{2+}$ , and phospholipids. The same peptide bond is also cleaved by FVIIa in the

presence of tissue factor in the extrinsic pathway of blood coagulation. FX is also converted to FXa by a specific enzyme in Russell's viper venom (RVV-X) [9]. The N-terminal catalytic domain of FX, which contains His236 and Asp282 of the catalytic triad, is an anion-binding exosite. The C-terminal domain, which contains Ser379, forms the oxyanion hole as the specific pocket for substrate binding. FXa combines with activated factor V in the presence of phospholipid and  $Ca^{2+}$  to form prothrombinase, which activates prothrombin to thrombin [10]. The crystal structure of human Des (1–45) FXa has been determined, and the active site is similar to that of thrombin [11].

Congenital FX deficiency, which was first described more than 40 years ago, was named 'Stuart/Prower deficiency' from the names of first two patients in whom it was identified [12]. To date, more than 50 gene mutations related to FX deficiency have been identified [13–24]. The cross-reactive material (CRM)-negative phenotype of FX deficiency is characterized by significant decreases of both FX activity and antigen levels, whereas the CRM-positive phenotype shows decreased FX activity but normal FX antigen levels.

Here we report the molecular analysis and functional consequence of the CRM-positive FX deficiency (Gly366Ser) in a French girl of Sri Lankan origin.

## Materials and methods


### Patient

The proband was an 11-year-old French female of Sri Lankan descent. She was diagnosed with FX deficiency on the basis of results from a preoperative hemostasis test prior to tonsillectomy when she was 4 years old. Her prothrombin time (PT) was 156 s (control, 12.8 s), and her activated partial thromboplastin time (aPTT) was 140 s (control, 34 s). She had a FX activity level of 1 U/dl (normal range, 70–138 U/dl), but her antigen level was 67% (normal range, 70–130%). At 9 years of age, she had a large hematoma in her right thigh after trauma and received prothrombin complex concentrate (PPSB) by transfusion for 8 days. At 10 years of age, she experienced a prolonged bleeding after a tooth extraction and required PPSB treatment for 3 days. At 11 years of age, she had menorrhagia with anemia (hemoglobin, 7 g/dl). The bleeding was stopped after antifibrinolytic therapy and PPSB transfusion. At that time, a hormonal substitutive treatment was started, and the gynecological bleeding was controlled. Her father, mother, and sister have FX activity levels of 58, 53, and 52 U/dl, and antigen levels of 89, 88, and 80%, respectively (Fig. 1).

### Isolation and characterization of the mutant F10 gene

The patient's parents gave their informed consent for blood sample collections and family genetic studies.

Fig. 1



Pedigree of the factor X (FX)-deficient family in the present study and plasma FX activity data. The proband is homozygous for a mutation causing FX deficiency. The father, mother, and sister are heterozygous for this position. FX activity was measured by a one-stage clotting assay based on the prothrombin time.

The complete nucleotide sequences of all eight exons and the exon/intron junctions of the F10 gene were determined in the proband. Polymerase chain reaction (PCR) primers flanking the 5' and 3' ends of each exon of the F10 gene were described previously [19,20]. Direct sequencing was done for all eight exons with an ABI Prism 377 (Applied Biosystems, Foster City, California, USA). For restriction fragment length polymorphism (RFLP) analysis of a single *A**lu*I site, the 163 base pair fragment of exon 8 was amplified with mutated primers 5'-GCAAGTGTCCACGAGTTT CATC and 5'-GCACAGCCCTCTCCCCAACTGACG (underlined bases are altered).

### Site-directed mutagenesis

The expression vector pCMV4/FX wild type, which contains FX cDNA including the complete FX coding sequence [22], a translation initiation sequence, and part of the 3' untranslated region, was a gift from Dr K. A. High (Children's Hospital of Philadelphia, Pennsylvania, USA). The point mutation responsible for the

amino acid change from Gly (GGC) to Ser (AGC) was introduced into the FX cDNA with a PCR-based technique. The mutagenic primers were forward primers 5'-GCGACAACAACCTCACGCGTATC and 5'-CTGTGCTAGCTACGACACC, and reverse primers 5'-GTCGTAGCTAGCACAGAAC and 5'-TGCAGGCATGCAAGCTTTGGCTG (underlined bases are altered). These primers create an *NheI* site adjacent to the point mutation without changing the encoded amino acid. The presence of the mutation and the orientation of the insert DNA were confirmed by direct sequencing with the ABI Prism 377. PCR amplification was performed for 25 cycles of denaturation (94°C, 15 s), annealing (58°C, 30 s), and extension (68°C, 60 s) using Platinum Pfx polymerase (Gibco BRL, Rockville, Maryland, USA).

#### Cell culture and transfection for *in vitro* expression

Human embryonic kidney cells (HEK293) were grown at 37°C in 5% CO<sub>2</sub> with Dulbecco's modified Eagle's medium (DMEM) media (Gibco BRL) supplemented with 10% (v/v) heat-inactivated fetal calf serum (Gibco BRL) and vitamin K<sub>1</sub> (Sigma-Aldrich Japan, Tokyo, Japan) to a final concentration of 6 µg/ml. Before transfection, the culture media were removed and replaced with serum-free DMEM including vitamin K<sub>1</sub>. Plasmid constructs [wild type, Gly366Ser, and 'mock' (pCMV4 vector only); 7.5 µg each] were transiently transfected into the cells with cationic lipid LipofectAmine™ 2000 reagent (Invitrogen, Carlsbad, California, USA). The cells were incubated for 24 h after transfection, and supernatants were collected for analysis.

#### Determination of FX antigen levels in culture media by enzyme-linked immunosorbent assay and analysis of FX molecular size by western blotting

Concentrations of FX antigen in the patient's plasma and culture media were determined with a FX enzyme-linked immunosorbent assay (ELISA) Kit (Stago Diagnostica, Paris, France) according to the manufacturer's instructions. Data are from three independent measurements. For western blot analysis, the culture media were subjected to 5–20% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis under non-reducing conditions. Proteins were transferred to nitrocellulose membranes, blocked with 5% powdered non-fat milk in TBS-T (20 mmol/l Tris-Cl, 500 mmol/l NaCl, pH 7.4, 0.5% Tween-20), and then incubated with horseradish peroxidase-conjugated rabbit anti-human FX antibody (DakoCytomation, Glostrup, Denmark). After two washes with TBS-T, the bound antibody was detected with a chemiluminescent kit (Amersham Bioscience, Piscataway, New Jersey, USA).

#### FX functional assays

Clotting assays of recombinant wild-type and mutant Gly366Ser FX secreted into the culture media were

performed with a CA-50 coagulometer (Sysmex, Kobe, Japan). FX antigen levels of wild-type and Gly366Ser FX in culture media were adjusted to 150 ng/ml by ELISA.

For analysis of FX activity in the extrinsic pathway (the PT), 50 µl supernatant from culture media diluted serially with serum-free DMEM and 50 µl FX-deficient plasma (Dade Behring Inc., Liederbach, Germany) were mixed and incubated for 3 min at 37°C. At the end of the incubation time, 100 µl thromboplastin C plus (Dade Behring) was added, and the clotting time was measured.

For analysis of FX activity in the intrinsic pathway (the aPTT), 50 µl supernatant diluted serially with serum-free DMEM and 50 µl FX-deficient plasma (Dade Behring) were mixed and incubated for 1 min at 37°C. At the end of the incubation time, 100 µl Actin® Activated Cephaloplastin Reagent (Dade Behring) was added, and the mixture was incubated for 2 min at 37°C. Then 50 µl of 20 mmol/l CaCl<sub>2</sub> was added, and the clotting time was measured.

For analysis of FX activity after activation with RVV, 50 µl supernatant diluted serially with serum-free DMEM and 50 µl FX-deficient plasma (Dade Behring) were mixed and incubated for 1 min at 37°C. At the end of the incubation time, 100 µl LA Test Gradipore (MBL, Tokyo, Japan) was added, and the clotting time was measured. For each analysis, the data from serially diluted wild-type supernatant were analyzed and curve fitting was performed using computer software (Statview 5.0; SAS International, Cary, North Carolina, USA) to generate a standard curve. The activity of Gly366Ser FX was expressed as a percentage of that of 1 × wild-type FX.

#### Chromogenic assay of FXa

The FX chromogenic activity against synthetic and macromolecular substrates was estimated with the FXa fluorogenic substrate S-2222 (50%/50% mixture of Bz-Ile-Glu (γ-OH)-Gly-Arg-pNa-HCl and Bz-Ile-Glu (γ-OCH<sub>3</sub>)-Gly-Arg-pNa-HCl; Chromogenix Instrumentation Laboratory SpA, Milan, Italy). Absorbance at 405 nm was measured with a multilabel counter for quantitative detection of light emission (Wallac1420; Perkin-Elmer, Turku, Finland).

Before chromogenic assays, we investigated an activation of recombinant FX with RVV. Fifty microliters of supernatant containing 2 nmol/l recombinant FX (wild type and Gly366Ser) was incubated for 5 min at 37°C with 0.01 U RVV-FX activator (Pentapharm, Basel, Switzerland). They were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis under non-reducing conditions, and estimated through wes-

tern blot analysis. Wild-type and mutant FX were equally digested under this condition (data not shown).

Fifty microliters of supernatant containing 2 nmol/l recombinant FX (mock, wild type, or Gly366Ser) was incubated for 5 min at 37°C with 0.01 U RVV-FX activator (Pentapharm). Then 1 mmol/l FXa fluorogenic substrate was added, and the absorbance at 405 nm was measured.

#### Thrombin generation assay

For the thrombin generation assay, FX-depleted plasma as a source of other essential factors for the coagulation cascade was diluted 1:25 in supernatant containing 2 nmol/l recombinant FX (mock, wild type, or Gly366Ser) and incubated for 2 min at 37°C with thromboplastin extracted from human placenta (Thromborel S; Dade Behring). Reactions were quenched with 25 mmol/l ethylene glycol bis(2-aminoethyl ether)-*N,N,N',N'*-tetraacetic acid, and absorbance at 405 nm was monitored with a multilevel counter for quantitative detection of light emission (Wallac1420; Perkin-Elmer).

#### Molecular modeling and comparative sequence analysis

The high-resolution crystal structure of wild-type FXa [11] was obtained from the protein structure databank (1XKA) and used as the basis to model the structure of mutant FXa (Gly366Ser). Comparative analyses of the mutant and wild-type FXa structures were performed with interactive graphics in a molecular operating environment (MOE; Chemical Computing Group, Inc., Montreal, Canada).

## Results


#### Characterization of the mutant F10 gene

The nucleotide sequences of all eight exons and exon/intron junctions of the F10 gene were determined for the proband. Sequence analysis revealed a single homozygous mismatch at position 363 (numbering according to GenBank accession number L29433) of exon 8, which results in the codon change Gly366 (GGC) to Ser (AGC). This mutation is similar to one reported previously (FX Nagoya) [14]. RFLP analysis confirmed that the proband was homozygous for this mutation, and all other family members (father, mother, and sister) tested were heterozygous (data not shown).

#### *In vitro* expression of FX Gly366Ser

Wild-type and mutant FX Gly366Ser were expressed using HEK293 cells, and the levels of secreted FX antigen in the culture media were determined by ELISA. The concentration of wild-type FX in culture media was  $189.4 \pm 5.1$  ng/ml and that of FX Gly366Ser was  $167.6 \pm 17.0$  ng/ml (Fig. 2). There was no significant difference between the levels of wild-type FX and

Fig. 2



Factor X (FX) antigen levels as determined by enzyme-linked immunosorbent assay in supernatants of HEK293 cells transfected with plasmid encoding wild-type FX or mutant FX Gly366Ser. 'Mock' indicates supernatants of HEK293 cells transfected with empty vector (pCMV). There was no significant difference between antigen levels of wild-type FX and FX Gly366Ser ( $P = 0.1007$ , unpaired Student's *t* test, performed in triplicate).

mutant FX ( $P = 0.1007$ , unpaired Student's *t* test, performed in triplicate).


On western blots, both wild-type FX and FX Gly366Ser present in culture media were detected as a single band under non-reducing conditions, and the molecular size was 59 kDa (Fig. 3).

#### Functional assays of FX Gly366Ser

The clotting activities of wild-type FX and FX Gly366Ser in culture media were evaluated with three types of activation procedures; extrinsic pathway (PT), intrinsic pathway (aPTT), and RVV activation (RVV time). The clotting activity of FX Gly366Ser was expressed as a percentage of the wild-type FX clotting activity. FX Gly366Ser clotting activities were only  $0.04 \pm 0.00\%$ ,  $1.05 \pm 0.04\%$ , and  $0.75 \pm 0.09\%$  of those of wild-type FX in the PT, aPTT, and RVV time assays, respectively (Table 1).

We next investigated the catalytic activity of recombinant FX Gly366Ser directly with a low molecular weight chromogenic substrate for FXa. After activation of wild-type FX or FX Gly366Ser by RVV in culture media, fluorogenic substrates of FXa were added, and the cleaved fluorescent peptides were detected quantitatively. The wild-type FXa catalyzed the substrate in a time-dependent manner; however, FXa Gly366Ser had no catalytic activity (Fig. 4).

Fig. 3




Western blot analysis of supernatants of HEK293 cells transfected with plasmid encoding wild-type factor X (FX) or mutant FX Gly366Ser. 'Mock' indicates supernatants of HEK293 cells transfected with empty vector (pCMV4). Under non-reducing conditions, wild-type FX and FX Gly366Ser were each detected as a single band (59 kDa).

We then performed a thrombin generation assay to confirm the enzymatic activity of FX Gly366Ser. Wild-type FX or FX Gly366Ser in culture media were mixed with FX-depleted plasma, activated with thromboplastin, and added to thrombin fluorogenic substrates. The cleaved fluorogenic peptides were then detected as markers of thrombin generation. The thrombin-generating activity of FX Gly366Ser was undetectable (Fig. 5).

#### Molecular modeling

The molecular modeling of FXa suggested that replacement of Gly366 with Ser in the catalytic domain could affect the interaction between the surrounding residues. The predicted distance between the  $C_{\beta}$  atom of Ser366 and the O atom of Ala365 is so narrowed (1.9 Å) as to ensure the collision of the two atoms (Fig. 6). This collision can be considered inevitable because the side chain of the  $C_{\beta}$  atom of Ser366 cannot rotate, and thus the Gly366Ser mutation would cause a conformational change of the domain that leads to loss of catalytic activity.

Fig. 4



Activity of recombinant factor X (FX) as measured with the chromogenic substrate of activated factor X (FXa). Supernatants containing wild-type FX or FX Gly366Ser were reacted with Russell's viper venom-FX activator and FXa fluorogenic substrate, and the absorbance at 405 nm was measured. Wild-type FX catalyzed the substrate in a time-dependent manner, whereas Gly366Ser had no catalytic activity. Mock, media from cells transfected with empty vector.

#### Discussion

Genetic analysis of the present case of congenital FX deficiency revealed the homozygous missense mutation in exon 8 of the F10 gene that results in substitution of serine for glycine at position 366. Two heterozygous patients have been previously described for this mutation [14,19], named FX Nagoya 2. In one report [14], a Japanese woman was a heterozygote and had FX activity and antigen levels of 34 and 80%, respectively. The present study is the first to describe an expression study of this mutation *in vitro*. The proband showed a severe hemorrhagic tendency and markedly prolonged PT and aPTT. The patient's FX antigen level was 67% of the normal value, and FX activity was only 1 U/dl, suggesting that this variant is not functional. RFLP analysis revealed that the proband's father, mother, and sister were heterozygous for the


Table 1 The clotting assay of recombinant wild-type factor X (FX) and FX Gly366Ser in culture media

	Prothrombin time (s)	Activated partial thromboplastin time (s)	Russell's viper venom time (s)
rFX wild-type	37.0 ± 0.3	66.3 ± 0.3	166.1 ± 0.6
rFX Gly366Ser	284.4 ± 1.5	185.4 ± 1.0	537.9 ± 9.6
(% wild type)	(0.04 ± 0.00)	(1.05 ± 0.04)	(0.75 ± 0.09)

Data presented as mean ± standard deviation, and all assays were performed in triplicate.



Fig. 5




Thrombin generation assay with recombinant factor X (FX). FX-depleted plasma was diluted 1 : 25 in supernatant containing 2 nmol/l recombinant FX (mock, wild type, or Gly366Ser) and incubated for 2 min at 37°C with thromboplastin. Then, 300 µmol/l thrombin fluorogenic substrates was added, and the fluorescence at 405 nm was monitored. The thrombin-generating activity of FX Gly366Ser was undetectable.

mutation, and the results of their phenotypic coagulation tests were consistent with the results of the genetic analyses.

*In vitro* expression study of FX Gly366Ser conferred significant findings to understand the proband's phenotype. Western blot analysis showed that both of the wild-type and Gly366Ser transfectants secreted FX antigen of the same molecular weight into culture media, indicating that this mutation would not have a major effect on the molecular size of the protein. The quantitative analysis of secreted FX antigen by ELISA showed a statistically equivalent level between Gly366Ser and wild type ( $P = 0.1007$ ), although there was a tendency of slightly lower level of Gly366Ser secretion. This result of ELISA might be related to the proband's slightly lower plasma FX antigen level (67%). Because our *in vitro* studies utilized a transient expression system, however, the meaning and significance of the FX antigen expression level should not be overestimated.

We performed functional characterization of FX Gly366Ser with the recombinant protein. The activities of the mutant in PT, aPTT, and RVV time assays were only  $0.04 \pm 0.00\%$ ,  $1.05 \pm 0.04\%$ , and  $0.75 \pm 0.09\%$  of

Fig. 6



Molecular modeling of activated factor X (FXa). Upper: three-dimensional structure of FXa. The structure of the Gla domain was predicted with 1DAN (activated factor VII with human recombinant soluble tissue factor) from a homology search of the Protein Data Bank. The structure of the Gla domain was linked to 1XKA (three-dimensional structure of FXa from the EGF domain to the serine protease domain), described previously [11], and the entire structure of FXa was then developed. Lower: close-up of the FXa Gly366Ser catalytic domain. Gly366Ser substitution results in an inevitable collision (1.9 Å) between the O atom of Ala365 and the C<sub>β</sub> atom of Ser366.

those of wild-type FX. Moreover, both the chromogenic FXa substrate and thrombin generation assays could not show any FX activity in the Gly366Ser mutant.

Gly366 is located in the serine protease subdomain 2 of the FX catalytic domain. When FX is activated, cleavage of the Arg194–Ile195 bond initiates the reaction and then the N-terminal residue of Ile195 forms an ion-pair with Asp378, which generates the oxyanion hole and exposure of the catalytic His236–Asp282–Ser379 triad [13]. Several mutations associated with CRM-positive FX deficiency are reported near Gly366. Among them, FX Roma (Thr317Met) [23], FX Marseille (Ser334Pro) [24], FX Friuli (Pro343Ser) [21], and FX Gly381Asp [18] have been well characterized. In these deficiencies, it is interesting that mutation to Ser occurs in both FX Friuli and FX Gly366Ser. In FX Friuli, a novel hydrogen bond between mutated Ser343 and Thr318 is thought to be formed, leading to perturbation of the structure of the substrate-binding pocket [21]. Molecular modeling of the FXa Gly366Ser by MOE predicted that the mutation would disrupt the native conformational structure of the catalytic domain (Fig. 6). Moreover, the Cys364–Ala365–Gly366 sequence in the catalytic domain is conserved in mammalian serine proteases, suggesting that these positions in the catalytic domain are important for the structure of mammalian serine proteases [25]. Taken together, these findings indicate that the Gly366Ser change would cause partial disruption of the catalytic domain, possibly through impaired protein folding, leading to catalytic dysfunction.

The severity of bleeding tendency in homozygous patients with CRM-positive FX deficiency was controversial. Most of them were affected mildly or moderately; and even in patients with severe hemorrhagic symptoms with the same homozygous mutation, the onset was markedly different [18]. Our case exhibited relatively severe hemorrhagic symptoms compared with other homozygous patients. This might be attributed to the extremely low activity of FXaGly366Ser suggested by RVV activation assay, FXa chromogenic assay and thrombin generation assay. Moreover, since FX forms a complex with factor V in the presence of Ca<sup>2+</sup> and phospholipids, the clinical bleeding feature could vary according to the effect of FX mutation on other components.

In conclusion, we presented here a new case of homozygous FX deficiency and data concerning the relations between structural and functional aspects of CRM-positive FX deficiency due to a Gly366Ser substitution. Our findings suggest that position 366 plays a critical role in wild-type FX catalytic function and that substitution with Ser results in loss of FX catalytic activity in the coagulation pathway.

## Acknowledgements

The authors thank Dr Rodney M. Camire and Dr Katherine A. High (Children's Hospital of Philadelphia) for kindly providing the FX cDNA and for their helpful advice on recombinant FX expression.

## References

- Davie EW, Fujikawa K, Kurachi K, Kisiel W. The role of serine proteases in the coagulation cascade. *Adv Enzymol Relat Areas Mol Biol* 1979; 48:277–318.
- Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX, factor X and protein S. *Biochemistry* 1977; 16:698–706.
- DeGrouchy J, Dautzenberg MD, Turleau C, Beguin S, Chavin-Colin F. Regional mapping of clotting factor VII and X to 13q34. Expression of factor VII through chromosome 8. *Hum Genet* 1984; 66:230–233.
- Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. *Cytogenet Cell Genet* 1985; 39:231–233.
- Royle NJ, Fung MR, MacGillivray RTA, Hamerton JL. The gene for clotting factor X is located on chromosome 13q34qter. *Cytogenet Cell Genet* 1986; 41:185–188.
- Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. *Biochemistry* 1986; 25:5098–5102.
- Greer J. Comparative model-binding of the mammalian serine proteases. *J Mol Biol* 1981; 153:1027–1042.
- Ahmad SS, Rawala-Sheikh R, Waish PN. Platelet receptor occupancy with factor IXa promotes factor X activation. *J Biol Chem* 1989; 264:20012–20016.
- Di Scipio RG, Hermodson MA, Davie EW. Activation of factor X (Stuart factor) by a protease from Russell's viper venom. *Biochemistry* 1977; 16:5253–5260.
- Chattopadhyay A, James HL, Fair DS. Molecular recognition sites on factor Xa which participate in the prothrombinase complex. *J Biol Chem* 1992; 267:12323–12329.
- Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, et al. Structure of human Des (1–45) Factor Xa at 2.2 Å resolution. *J Mol Biol* 1993; 232:947–966.
- Graham JB. Stuart Factor: discovery and designation as factor X. *J Thromb Haemost* 2003; 1:871–877.
- Cooper DN, Millar DS, Wacey A, Pemberton S, Tuddenham EGD. Inherited factor X deficiency: molecular genetics and pathophysiology. *Thromb Haemost* 1997; 78:161–172.
- Miyata T, Kojima T, Suzuki K, Umeyama H, Yamazaki T, Kamiya T, et al. Factor X Nagoya 1 and Nagoya 2: a CRM-factor X deficiency and a dysfunctional CRM<sup>+</sup> factor X deficiency by substitution of Arg306 by Cys and of Gly 366 by Ser, respectively. *Thromb Haemost* 1998; 79:486–490.
- Zama T, Murata M, Watanabe R, Yokoyama K, Moriki T, Ambo H, et al. A family with hereditary factor X deficiency with a point mutation Glu32 to Gln in the Gla domain (factor X Tokyo). *Br J Haematol* 1999; 106:809–811.
- Peyvandi F, Menegatti M, Santagostino E, Akhavan S, Uprichard J, Perry JD, et al. Gene mutations and three-dimensional structure analysis in 13 families with severe factor X deficiency. *Br J Haematol* 2002; 117:685–692.
- Pinotti M, Marchetti G, Baroni M, Cinotti F, Morfini M, Bernardi F. Reduced activation of the Glu19Ala FX variant via the extrinsic coagulation pathway result in symptomatic CRM<sup>red</sup> FX deficiency. *Thromb Haemost* 2002; 88:236–241.
- Pinotti M, Camire RM, Baroni M, Rajab A, Marchetti G, Bernardi F. Impaired prothrombinase activity of factor X Gly381Asp results in severe familial CRM<sup>+</sup> FX deficiency. *Thromb Haemost* 2003; 89:243–248.
- Miller DS, Elliston L, Deex P, Krawczak M, Wacey AI, Reynaud J, et al. Molecular analysis of the genotype-phenotype relationship in factor X deficiency. *Hum Genet* 2000; 106:249–257.
- Reddy SV, Zhou ZQ, Rao KJ, Scott JP, Watzke H, High KA, et al. Molecular characterization of human factor X San Antonio. *Blood* 1989; 74:1486–1490.
- Kim DJ, Girolami A, James HL. Characterization of recombinant human coagulation factor X Friuli. *Thromb Haemost* 1996; 75:313–317.
- Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor X Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. *J Clin Invest* 1991; 88:1685–1689.

- 23 De Stefano V, Leone G, Ferrelli R, Hassan HJ, Macioce G, Bizzi B. Factor X Roma: a congenital factor X variant defective at different degrees in the intrinsic and the extrinsic activation. *Br J Haematol* 1988; **69**:387-391.
- 24 Bezeaud A, Miyata T, Helley D, Zeng YZ, Kato H, Aillaud MF, *et al*. Functional consequences of the Ser334-Pro mutation in a human factor X variant (factor X Marseille). *Eur J Biochem* 1995; **234**:140-147.
- 25 Lesk AM, Fordham WD. Conservation and variability in the structures of serine proteases of the chymotrypsin family. *J Mol Biol* 1996; **258**: 501-537.

## Original Article

Increased Risk of Obesity Resulting from the Interaction between High Energy Intake and the Trp64Arg Polymorphism of the  $\beta$  3-adrenergic Receptor Gene in Healthy Japanese Men

Koichi Miyaki,<sup>1</sup> Shinya Sutani,<sup>1</sup> Haruhito Kikuchi,<sup>2</sup> Izumi Takei,<sup>2,3</sup> Mitsuru Murata,<sup>2,3</sup> Kiyooki Watanabe,<sup>2</sup> and Kazuyuki Omae.<sup>1</sup>

**BACKGROUND:** Few studies have investigated the interaction between the Trp64Arg polymorphism of the  $\beta$  3-adrenergic receptor gene (*ADRB3*) and environmental factors. This study aimed to investigate whether energy intake affects the relationship between this polymorphism and obesity.

**METHODS:** Healthy Japanese men (n=295; age 46.1±11.5 years (mean ± standard deviation); waist circumference 83.9±9.3 cm; body mass index (BMI) 23.3±3.3 kg/m<sup>2</sup>) recruited in a Japanese chemical industry firm were eligible for analysis. Daily energy intake, protein, fat, and carbohydrate (PFC) ratio and daily physical activity were assessed by self-reported questionnaires. Genotyping for the polymorphism was performed with written informed consent.

**RESULTS:** When the subjects were classified into two groups according to presence of the polymorphism, the groups were not significantly different in waist circumference or BMI. Quartile classification of energy intake, however, demonstrated a significantly larger ratio of obese subjects to non-obese subjects in the group with the polymorphism in the highest 4th quartile alone. Multiple logistic regression analysis also revealed that the presence of the polymorphism increased the risk of obesity significantly in the 4th quartile alone (adjusted odds ratio=3.37, 95% confidence interval=1.12-10.2).

**CONCLUSION:** Presence of the polymorphism alone does not significantly increase the risk of obesity. However, high energy intake interacts with the polymorphism and leads to a significant increase in risk of obesity. The Trp64Arg polymorphism of *ADRB3* warrants consideration, along with other polymorphisms involved in the development of obesity, for tailor-made prevention of obesity.

*J Epidemiol* 2005; 15:203-210.

Key words: Obesity; Receptors, Adrenergic, beta-3; Polymorphism, Single Nucleotide; Energy Intake; Questionnaires.

Obesity is attributable to the effects of genetic and environmental factors, and it affects human health.<sup>1</sup> Accumulation of visceral fat, in particular, may play an important role in the pathogenesis of glucose intolerance, hyperlipidemia, and hypertension, and the accumulation of visceral fat is closely linked with atherosclerosis.<sup>2,4</sup>

Many genes are suspected to be associated with obesity,<sup>5</sup> and recently the  $\beta$  3-adrenergic receptor gene (*ADRB3*) has become

the center of attention. In humans *ADRB3* is predominantly expressed in visceral adipose tissue.<sup>6</sup> It contains seven transmembrane domains and is coupled with G proteins.<sup>7</sup> Stimulation of the *ADRB3* by  $\beta$ -adrenergic agonists has been demonstrated to activate adenylate cyclase, which increases the intracellular cyclic AMP level and leads to acceleration of lipid metabolism and thermogenesis.<sup>7</sup>

Received April 6, 2005, and accepted June 10, 2005.

This research was supported by the Ministry of Economy, Trade and Industry, Japan (R&D for practical use of university-based technology by matching government and private funds).

<sup>1</sup> Department of Preventive Medicine and Public Health, School of Medicine, Keio University.

<sup>2</sup> Department of Laboratory Medicine, School of Medicine, Keio University.

<sup>3</sup> Department of Internal Medicine, School of Medicine, Keio University.

Address for correspondence: Koichi Miyaki, M.D. Department of Preventive Medicine and Public Health, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. (e-mail: miyaki@sc.itc.keio.ac.jp)

Copyright © 2005 by the Japan Epidemiological Association

In 1995, Pima Indians, an ethnic group with a very high prevalence of obesity and non-insulin-dependent diabetes mellitus (NIDDM), were found to have a high frequency of the Trp64Arg polymorphism due to the replacement of thymidine (T) by cytosine (C) at nucleotide position 190 in *ADRB3*, and those with the polymorphism were found to have early onset of NIDDM and a low resting metabolic rate.<sup>8</sup> Subjects with the polymorphism in France have been found to have increased capacity to gain weight,<sup>9</sup> and the polymorphism is associated with abdominal obesity in Finns and may cause insulin resistance and earlier onset of NIDDM in that population.<sup>10</sup>

The polymorphism has been detected at an allelic frequency of about 0.20 in Japanese, which is lower than in Pima Indians (0.31) and higher than in Mexican-Americans (0.13), Blacks (0.12) and Whites (0.08) in the United States.<sup>8,11</sup> The resting metabolic rate of obese Japanese women with the polymorphism is about 200 kcal/day lower than of those without the polymorphism, and women with the polymorphism have difficulty in losing weight.<sup>12</sup> Moreover, the polymorphism has been found to be associated with visceral-fat obesity and insulin resistance syndrome, and it may be possible to use the polymorphism as a genetic marker for these syndromes.<sup>13</sup> Other studies have also shown that the polymorphism is associated with obesity<sup>14,15</sup> and insulin resistance.<sup>15</sup>

A meta-analysis of the association between the polymorphism of *ADRB3* and body mass index (BMI) in 31 studies demonstrated that subjects with the polymorphism had a BMI that averaged 0.30 (95% confidence interval [CI]=0.13-0.47) higher than those without the polymorphism.<sup>16</sup>

Many studies have demonstrated that the polymorphism of *ADRB3* is associated with obesity, but few studies have shown that it is possible to prevent or treat obesity and its complications in persons with the polymorphism. Therefore, to achieve tailor-made prevention or treatment based on genotype, including *ADRB3*, we investigated the interaction between energy intake and the polymorphism in *ADRB3* in healthy Japanese men.

## METHODS

This study was approved by the Institutional Review Board (IRB) of Keio University School of Medicine, and was carried out in concordance with the principles of the Declaration of Helsinki. We explained this study by means of a written document to healthy Japanese men and women working for a company in Kanagawa prefecture and obtained written informed consent from 363 workers (male: 326, female: 37) to participate in the study, which included genotyping. The following surveys and genotyping for the polymorphism of *ADRB3* were conducted in October and November 2003, and we obtained complete replies to the food frequency questionnaire (FFQ) from 337 (male: 295, female: 32) of the 363 workers, who were genotyped for the polymorphism of *ADRB3*. Allowing for the fact that the Japan Society for the Study of Obesity established different criteria for 'obesity dis-

ease' in men and women,<sup>17</sup> and the report that men might have a higher risk of coronary heart disease than women due to the difference in body fat distribution,<sup>18</sup> we performed the analysis focused on the 295 male workers.

Their mean age, waist circumference, and BMI (mean  $\pm$  standard deviation) were  $46.1 \pm 11.5$  years,  $83.9 \pm 9.3$  cm, and  $23.3 \pm 3.3$  kg/m<sup>2</sup>, respectively. Height, weight, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose level, and serum lipid levels were measured in all the subjects. A Body mass index (BMI) was calculated as weight (kg)/height<sup>2</sup> (m<sup>2</sup>). Obesity was defined as BMI  $\geq 25$  kg/m<sup>2</sup> or waist circumference  $\geq 85$  cm, based on the criteria for 'obesity' of the Japan Society for the Study of Obesity.<sup>17</sup> In addition, information on the age, physical activity, smoking status, energy intake, and the protein, fat, and carbohydrate (PFC) ratio of all the subjects was obtained by means of a self-report questionnaire. The semi-quantitative food frequency questionnaire (FFQ), which was evaluated by comparing the FFQ with the 7-day dietary records of 66 subjects by Takahasi K, et al.<sup>19</sup>, was used to calculate energy intake and PFC ratio. Takahasi K, et al. reported that the correlation coefficients between the FFQ and the 7-day dietary records for energy, protein, fat, and carbohydrate intake were 0.47 ( $p < 0.001$ ), 0.42 ( $p < 0.001$ ), 0.39 ( $p < 0.01$ ), and 0.49 ( $p < 0.001$ ), respectively.<sup>19</sup>

Daily physical activity was calculated based on hours per day subjects engaged in each activity. The intensity of each activity was quantified by assigning metabolic equivalents (METs) to each activity.<sup>20</sup> METs represent the ratio of energy expended during each specific activity to resting metabolic rate. The time spent in each activity was multiplied by the specific number of METs assigned to each activity, and the products were summed. The sum was defined as the daily physical activity (METs  $\cdot$  minutes) of each subject.

The FFQ used in this study asked about the consumption of food items in 29 food groups during the previous one or two months. Basically, the subjects were asked to describe the quantities and frequencies of consumption of food items during breakfast, lunch, and dinner. Three portion size categories (small, medium, and large) were used to evaluate the quantities of consumption of food items. "Small" is half the size of "medium", and "large" is one and a half times the size of "medium". When the frequency of consumption of a food is less than once or twice a month, the subject is instructed to answer "never". The FFQ illustrated the food items of each food group in quantity equal to "medium", so as to evaluate the quantities of consumption correctly. When the frequency of consumption of a food was low, the subjects were asked to answer the quantity of consumed at one time and the frequency of consumption per week. Foods of this kind included sea vegetables, fruit, potatoes, butter, pickles, etc. The subjects were also asked to describe the quantity of consumption at one time and the frequency of consumption per week of alcoholic and non-alcoholic beverages. When the quantity of a unit of a food was almost identical among subjects, the subjects were asked to state only the frequency of consumption per week

as the number of consumed units. Foods of this kind included rice, milk, egg, etc. Daily nutrient intake was calculated by multiplying the frequency of consumption of each food by the nutrient content of the portion size and summing the products for all foods items. The energy intake and PFC ratio of each subject were determined in this manner.

A peripheral blood specimen was collected from each subject, and genotyping for the polymorphism of *ADRB3* was performed by polymerase chain reaction (PCR) and single nucleotide primer extension (SNUPE) assay with Ampdirect (Shimadzu Corporation, Kyoto, Japan), which eliminates the DNA extraction process and amplifies the genomic DNA directly from the whole blood.

A 367-bp fragment of the gene encompassing the polymorphism site was amplified by PCR using 5'-primer (5'TTCCTTCTTTCCCTACCGCCC)<sup>8</sup> and 3'-primer (5'GCAGCCAGTG-GCGCCCAACGG)<sup>8</sup>. The PCR reactions were carried out in the PCR mixture containing 10  $\mu$ L of Ampdirect-G/C (Shimadzu Corporation, Kyoto, Japan), 10  $\mu$ L of Ampdirect Addition (Shimadzu Corporation, Kyoto, Japan), 4  $\mu$ L of dNTP mixture (TaKaRa Bio Inc., Shiga, Japan), 0.5  $\mu$ M of 5'-primer,<sup>8</sup> 0.5  $\mu$ M of 3'-primer,<sup>8</sup> 0.25  $\mu$ L of *Taq* DNA Polymerase (Promega Corporation, Wisconsin, USA), up to 50  $\mu$ L of distilled water, and 1.0  $\mu$ L of whole blood. The PCR consisted of preheating at 80°C for 15 minutes; denaturation at 94°C for 4.5 minutes; 40 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 1 minute, and extension at 72°C for 1 minute; a final extension at 72°C for 7 minutes. The SNUPE assay was then performed. The SNUPE assay was based on the incorporation of a single fluorescent-labeled ddNTP, which was correctly paired with the template DNA and caused chain-termination, to the 3' terminus of a primer annealed next to the polymorphic site.<sup>21</sup> The SNUPE primer (5'ATGGTCTGGAGTCTCGGAGTCC) was designed so that the primer ends immediately before the polymorphic site. The SNUPE reactions were carried out in the mixture; containing 2  $\mu$ L of PCR product, 4  $\mu$ L of SNUPE premix (ddATP, ddCTP, ddGTP, ddTTP, DNA polymerase), and 2 pM of SNUPE primer. The SNUPE consisted of 25 cycles of denaturation at 94°C for 10 seconds, annealing at 53°C for 5 seconds, and extension at 60°C for 10 seconds. The products were analyzed with ABI 7700 (Applied Biosystems, California, USA).

For statistical analysis, Student's t-test was used to compare normally distributed variables between groups. Variables that were not normally distributed were log transformed. When the log transformations of the variables were effective, Student's t-test was used. When ineffective, the Wilcoxon rank-sum test was used. The  $\chi^2$  test was used to compare categorical variables. Multiple logistic regression analysis was performed on obesity defined as waist circumference 85+ cm,<sup>17</sup> with presence of the polymorphism of *ADRB3*, age, smoking, and physical activity as variables.

Differences were assessed by two-sided tests, with an alpha level of 0.05. All statistical analyses were performed with

Statistical Package for the Social Sciences\* (SPSS) for Windows, version 11 software (SPSS Inc., Illinois, USA).

## RESULTS

Genotyping for the Trp64Arg polymorphism of *ADRB3* in the 295 healthy Japanese male subjects showed that 198 were homozygous for the wild-type allele (Trp/Trp), 94 were heterozygous for the variant allele (Arg/Trp), and 3 were homozygous for the variant allele (Arg/Arg) (allelic frequency=0.17). These results were in Hardy-Weinberg equilibrium and did not conflict with the results previously reported in another Japanese population ( $p=0.240$ ).<sup>13</sup>

The main characteristics of the subjects are shown in Table 1. There were no significant differences between the subjects with and without the polymorphism with regard to age, height, weight, BMI, waist circumference, systolic or diastolic blood pressure, fasting plasma glucose, triglyceride, or HDL cholesterol levels, PFC ratio (fat, carbohydrate), energy intake, physical activity, or smoker/non-smoker ratio. The total cholesterol values and PFC ratio (protein) of the subjects with the polymorphism were significantly lower than the subjects without the polymorphism ( $p=0.016$  and  $0.026$ , respectively).

The subjects were classified into quartiles according to energy intake based on their replies to the FFQ. The mean waist circumference and BMI values in each quartile are shown in Table 2. There were no significant differences in waist circumference between the subjects in the 1st quartile and the subjects in the other quartiles. There was a significant difference in BMI between the subjects in the 1st quartile and in the 4th quartile ( $p=0.035$ ), but not between the subjects in the 1st quartile and the subjects in the 2nd or the 3rd quartile. In addition, the trend test showed progressive increases in waist circumference and BMI in the quartiles that paralleled increased levels of energy intake ( $p=0.043$  and  $0.024$ , respectively).

We then divided each quartile into two groups according to presence of the polymorphism and calculated the ratio of the obese to the non-obese subjects in each group (Tables 3 and 4). When subjects with waist circumference 85+ cm<sup>17</sup> were defined as obese (Table 3) in the 2nd quartile, the ratio of the group with the polymorphism was significantly lower than that of the group without the polymorphism (odds ratio [OR]=0.278, 95% CI=0.10-0.78), and in the 4th quartile, the ratio of the group with the polymorphism was significantly higher than that of the group without the polymorphism (OR=3.490, 95% CI=1.24-9.85).

When subjects with BMI 25+ kg/m<sup>2</sup><sup>17</sup> were defined as obese, no significant difference between the ratio of obese to non-obese subjects in the group with the polymorphism and the group without the polymorphism was seen in any of the quartile (Table 4).

The results of the multiple logistic regression analysis on obesity (defined as waist circumference 85+ cm<sup>17</sup>) in the 4th quartile (total: 74, without polymorphism: 48, with polymorphism: 26) are shown in Table 5, in which the presence of *ADRB3* polymor-

phism, smoking, age and physical activity were independent variables. Only the presence of the polymorphism of *ADRB3* was associated with increased risk of obesity (adjusted OR=3.37, 95% CI=1.12-10.16). The results of the multiple logistic regression

analyses on obesity defined as waist circumference 85+ cm<sup>17</sup> and the same variables demonstrated that presence of the polymorphism of *ADRB3* was not associated with increased risk of obesity in the 1st, 2nd, and 3rd quartile.

**Table 1.** Clinical characteristics of the subjects, according to the ADRB3 polymorphism.

	All subjects	ADRB3 genotype		p value
		without polymorphism (Trp/Trp)	with polymorphism (Trp/Arg or Arg/Arg)	
n	295	198	97	
Age (years)*	46.1 ± 11.5	46.5 ± 11.3	45.3 ± 11.9	0.300
Height (cm)	168.6 ± 6.26	168.3 ± 6.19	169.1 ± 6.41	0.289
Weight (kg)	66.3 ± 10.4	66.3 ± 10.3	66.3 ± 10.6	0.999
Body mass index (kg/m <sup>2</sup> )	23.3 ± 3.28	23.4 ± 3.20	23.2 ± 3.47	0.633
Waist circumference (cm)	83.9 ± 9.30	84.1 ± 9.19	83.5 ± 9.57	0.636
Systolic blood pressure (mmHg)	134.4 ± 18.0	134.0 ± 18.5	135.2 ± 16.8	0.582
Diastolic blood pressure (mmHg)	81.7 ± 12.7	81.4 ± 13.1	82.3 ± 11.8	0.576
Fasting plasma glucose (mg/dL)†	100.2 ± 34.0	99.2 ± 31.8	102.5 ± 38.5	0.481
Total cholesterol (mg/dL)	206.9 ± 37.0	210.6 ± 35.8	199.3 ± 38.6	0.016
Triglyceride (mg/dL)†	131.9 ± 83.1	134.2 ± 86.1	127.1 ± 76.6	0.664
HDL cholesterol (mg/dL)	55.5 ± 14.0	55.5 ± 12.8	55.4 ± 16.4	0.976
Protein, fat, and carbohydrate ratio (%)				
Protein (%)	13.9 ± 2.39	14.1 ± 2.48	13.5 ± 2.14	0.026
Fat (%)	27.6 ± 5.36	27.7 ± 5.48	27.6 ± 5.13	0.890
Carbohydrate (%)	58.5 ± 6.88	58.2 ± 7.06	59.0 ± 6.51	0.379
Energy intake (kcal/day)	1855.3 ± 485.0	1857.3 ± 509.2	1851.3 ± 433.9	0.920
Physical activity (METs · minutes)	2457.0 ± 710.9	2479.2 ± 763.8	2409.6 ± 583.6	0.442
Smoker/Non-smoker‡	175/119	112/85	63/34	0.184

Values are means ± standard deviation. Subjects with polymorphism were compared with subjects without polymorphism.

Basically, we used Student's *t*-test. As to variables with mark, we analyzed as follow.

\* : Wilcoxon rank-sum test.

† : Variable was log transformed, and the Student's *t*-test was used. Data is pre-log transformed.

‡ :  $\chi^2$  test.

**Table 2.** The mean waist circumference and body mass index values in each quartile, according to the energy intake.

	Energy intake				trend test
	1st quartile (-1515 kcal/day)	2nd quartile (1516-1795 kcal/day)	3rd quartile (1796-2131 kcal/day)	4th quartile (2132+ kcal/day)	
n	73	74	74	74	
Waist circumference (cm)	82.6 ± 9.53	82.9 ± 8.33	84.9 ± 9.02	85.2 ± 10.1	0.043
Body mass index (kg/m <sup>2</sup> )	22.6 ± 3.28	23.2 ± 3.24	23.6 ± 3.33	23.8 ± 3.24*	0.024

Values are means ± standard deviation. Subjects in the 2nd, 3rd, and 4th quartile were compared with subjects in the 1st quartile.

We used Student's *t*-test and trend test.

\* : P<0.05 for Student's *t*-test.

**Table 3.** The ratio of the obese (waist circumference 85+ cm) to the non-obese (waist circumference less than 85 cm) by the ADRB3 polymorphism.

	ADRB3 genotype		both
	without polymorphism (Trp/Trp)	with polymorphism (Trp/Arg or Arg/Arg)	
1st quartile			
n (the obese/the non-obese)	24/26	8/15	32/41
the ratio of the obese to the non-obese	0.92	0.53	0.78
2nd quartile			
n (the obese/the non-obese)	24/21	7/22*	31/43
the ratio of the obese to the non-obese	1.14	0.32	0.72
3rd quartile			
n (the obese/the non-obese)	31/23	9/10	40/33
the ratio of the obese to the non-obese	1.35	0.90	1.21
4th quartile			
n (the obese/the non-obese)	21/27	19/7*	40/34
the ratio of the obese to the non-obese	0.78	2.71	1.18
all subjects			
n (the obese/the non-obese)	100/97	43/54	143/151
the ratio of the obese to the non-obese	1.03	0.80	0.95

The ratio of the obese to the non-obese in the group with the polymorphism was compared with that in the group without the polymorphism in each quartile. We used  $\chi^2$  test.

\* :  $P < 0.05$ .

**Table 4.** The ratio of the obese (body mass index 25+ kg/m<sup>2</sup>) to the non-obese (body mass index less than 25 kg/m<sup>2</sup>) by the ADRB3 polymorphism.

	ADRB3 genotype		both
	without polymorphism (Trp/Trp)	with polymorphism (Trp/Arg or Arg/Arg)	
1st quartile			
n (the obese/the non-obese)	12/38	5/18	17/56
the ratio of the obese to the non-obese	0.32	0.28	0.30
2nd quartile			
n (the obese/the non-obese)	14/31	6/23	20/54
the ratio of the obese to the non-obese	0.45	0.26	0.37
3rd quartile			
n (the obese/the non-obese)	17/38	6/13	23/51
the ratio of the obese to the non-obese	0.45	0.46	0.45
4th quartile			
n (the obese/the non-obese)	16/32	11/15	27/47
the ratio of the obese to the non-obese	0.50	0.73	0.57
all subjects			
n (the obese/the non-obese)	59/139	28/69	87/208
the ratio of the obese to the non-obese	0.42	0.41	0.42

The ratio of the obese to the non-obese in the group with the polymorphism was compared with that in the group without the polymorphism in each quartile. We used  $\chi^2$  test.



**Table 5.** The multiple logistic regression analysis on obesity defined as waist circumference 85+ cm in the 4th quartile.

Explanatory variables	Adjusted odds ratio(95% confidence interval)
Presence of the polymorphism of <i>ADRB3</i>	3.37 (1.12-10.16)
Age (per year)	1.04 (1.00-1.08)
Smoking (smoker/non-smoker)	0.48 (0.17-1.37)
Physical activity (per 1000 METs·minutes)	0.76 (0.40-1.46)

Presence of the polymorphism of *ADRB3*, age, smoking, and physical activity were considered as variables.

## DISCUSSION

In this study, we classified the subjects into quartiles according to energy intake based on the replies to the FFQ. The values for energy intake based on the FFQ in this study were slightly lower than the National Nutrition Survey in 2002,<sup>22</sup> which were based on diet records. The discrepancy is thought to be due to a failure to list all food items consumed by the subjects in the period due to the limitation on the number of food items listed in the FFQ. The FFQ has been reported to underestimate the absolute level of consumption of nutrients and food groups compared to diet records.<sup>23,24</sup> However, it has been also reported that while the FFQ underestimates the absolute levels of consumption of nutrients and food groups, it is reasonably valid in ranking subjects and classifying them into quintiles according to the consumption of many nutrients and food groups.<sup>23</sup> Furthermore, the percentages of complete agreement, adjacent agreement, and complete disagreement according to tertile classification of daily energy intake based on diet records and FFQ have been found to be 56%, 36%, and 7%, respectively.<sup>24</sup> Thus, while energy intake based on the FFQ may only be a semi-quantitative index, it can be concluded to be an accurate means of classifying subjects into quartiles.

When the subjects were classified into two groups according to presence of the polymorphism, the total cholesterol values and PFC ratio (protein) of the subjects with the polymorphism were significantly lower than those of subjects without the polymorphism. Even if the function of the *ADRB3* is considered,<sup>7</sup> these results are of unexplained origin.

The trend test showed progressive increases in waist circumference and BMI in the quartiles that paralleled increased levels of energy intake (Table 2). Furthermore, when subjects with a waist circumference 85+ cm<sup>17</sup> were defined as obese, the ratio in the group with the polymorphism was slightly but not significantly lower in the 1st and 3rd quartile, significantly lower in the 2nd quartile, and significantly higher in the 4th quartile (Table 3). These results indicate that increased energy intake may increase the risk of obesity without regard to the presence of the polymorphism of *ADRB3* and indicate that the combination of high energy intake and the presence of the polymorphism of *ADRB3* make this polymorphism a risk factor for obesity. Moreover, these results indicate that the combination of proper energy intake and the presence of the polymorphism of *ADRB3* may tend to reduce the risk of obesity. The hypothesis that the presence of the polymorphism of *ADRB3* alone does not affect the risk of obesity is sup-

ported by the finding that when the subjects were classified into two groups according to presence of the polymorphism, no significant difference in waist circumference or BMI was seen between the subjects with and without the polymorphism ( $84.1 \pm 9.19$  vs  $83.5 \pm 9.57$ , and  $23.4 \pm 3.20$  vs  $23.2 \pm 3.47$ , respectively) (Table 1).

The results of the multiple logistic regression analysis showing that the presence of the polymorphism of *ADRB3* increases the risk of obesity in the 4th quartile alone (Table 5) also suggests interaction between high energy intake and the polymorphism of *ADRB3*.

A study comparing BMI, waist circumference, and waist-hip ratio (WHR) in regard to their respective associations with accumulation of abdominal visceral adipose tissue showed that the highest significant positive correlation was between waist circumference and abdominal visceral adipose tissue area measured by computed tomography in both men and women ( $r=0.77$  and  $0.87$ , respectively).<sup>25</sup> When obesity was defined according to waist circumference not BMI in the present study, the interaction between the polymorphism of *ADRB3* and high energy intake was found to increase the risk of obesity. This finding indicates that the polymorphism of *ADRB3* is associated with visceral-fat obesity, which is supported by the finding that in humans *ADRB3* is predominantly expressed in visceral fat.<sup>6</sup> The polymorphism of *ADRB3* has previously been reported to be associated with visceral-fat obesity,<sup>13,26</sup> and the results of the present study do not contradict these reports.

Adipose tissue functions as a secretory tissue producing various adipocytokines including leptin, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), plasminogen activator inhibitor type I (PAI-1), and adiponectin.<sup>27-30</sup> It is reported that adiponectin has anti-diabetic,<sup>31</sup> anti-atherogenic,<sup>32</sup> and anti-inflammatory biofunctions,<sup>33</sup> and that the plasma levels of adiponectin decreased with the accumulation of visceral adipose tissue.<sup>34</sup> It is also reported that intra-abdominal fat area was significantly associated with all of the metabolic syndrome criteria, including blood pressure, waist circumference, HDL cholesterol, triglyceride level, and fasting plasma glucose level,<sup>35</sup> independent of insulin sensitivity and subcutaneous fat area. In addition intra-abdominal fat area was independently associated with development of metabolic syndrome (adjusted OR=2.43, 95% CI=1.33-4.47).<sup>36</sup> Moreover, in the study based on 11 prospective European cohort studies involving 6156 men and 5356 women without diabetes, the overall hazard ratios for all-cause and cardiovascular disease mortality in subjects with the

metabolic syndrome compared with those without the syndrome were 1.44 (95% CI=1.17-1.84) and 2.26 (95% CI=1.61-3.17) in men and 1.38 (95% CI=1.02-1.87) and 2.78 (95% CI=1.57-4.94) in women after adjustment for age, blood cholesterol levels, and smoking.<sup>37</sup> Therefore, it is possible that prevention or treatment of visceral fat obesity, which is said to be associated with the polymorphism of *ADRB3*, could lead to reduced mortality associated with the metabolic syndrome.

The results of the present study demonstrated that the polymorphism of *ADRB3* alone does not increase the risk of obesity and that the environmental factor of high energy intake interacts with the polymorphism and leads to the significant increase in risk of obesity. This indicates the possibility that subjects with the Trp64Arg polymorphism can avoid the increase in the risk of obesity by proper energy intake control. Therefore, the Trp64Arg polymorphism may be a factor that we should take into consideration when we aim to tailor-made prevention or treatment of obesity. However, the findings that no significant difference in waist circumference or BMI was seen between the subjects with and without the polymorphism indicate that the effect of the polymorphism in the development of obesity is rather small and that it may be difficult to carry out tailor-made prevention or treatment of obesity based on genotyping of the Trp64Arg polymorphism of *ADRB3* alone. Further studies investigating the interaction between the Trp64Arg polymorphism of *ADRB3* and other polymorphisms involved in the development of obesity, will be needed.

## ACKNOWLEDGMENTS

We are grateful to Mrs. Maria Kanetake for her support in the statistical analysis and to Mr. Shugo Tohyama for his support in the laboratory work. We also thank Drs. Shinzo Kato, Yoko Kawai, Shiro Iwanaga, and Takeyuki Mitsuhashi for their assistance in this research project.

## REFERENCES

1. Kopelman PG. Obesity as a medical problem. *Nature* 2000; 404: 635-43.
2. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. *Metabolism* 1987; 36: 54-9.
3. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Nagai Y, et al. Close correlation of intra-abdominal fat accumulation to hypertension in obese women. *Hypertension* 1990; 16: 484-90.
4. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. *Diabetes Care* 1996; 19: 287-91.
5. Snyder EE, Walts B, Perusse L, Chagnon YC, Weisnagel SJ, Rankinen T, et al. The human obesity gene map: the 2003 update. *Obes Res* 2004; 12: 369-439.
6. Krief S, Lonnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. *J Clin Invest* 1993; 91: 344-9.
7. Emorine LJ, Marullo S, Briand-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. *Science* 1989; 245: 1118-21.
8. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. *N Engl J Med* 1995; 333: 343-7.
9. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. *N Engl J Med* 1995; 333: 352-4.
10. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. *N Engl J Med* 1995; 333: 348-51.
11. Arner P, Hoffstedt J. Adrenoceptor genes in human obesity. *J Intern Med* 1999; 245: 667-72.
12. Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. *Lancet* 1995; 346: 1433-4.
13. Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta 3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and insulin resistance syndrome. *Diabetologia* 1997; 40: 200-4.
14. Endo K, Yanagi H, Hirano C, Hamaguchi H, Tsuchiya S, Tomura S. Association of Trp64Arg polymorphism of the beta 3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. *Int J Obes Relat Metab Disord* 2000; 24: 443-9.
15. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, et al. A mutation in beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. *Biochem Biophys Res Commun* 1995; 215: 555-60.
16. Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. *J Clin Endocrinol Metab* 1998; 83: 2441-4.
17. Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. *Circ J* 2002; 66 :987-92.
18. Larsson B, Bengtsson C, Björntorp P, Lapidus L, Sjöström L, Svärdsudd K, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. *Am J Epidemiol* 1992; 135: 266-73.
19. Takahasi K, Yoshimura Y, Kaimoto T, Kunii D, Komatsu T,

- Yamamoto S. Validation of a food frequency questionnaire based on food groups for estimating individual nutrient intake. *Jpn J Nutr* 2001; 59: 221-32. (in Japanese)
20. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc* 2000; 32 (9 Suppl): S498-S516.
  21. Kuppaswamy MN, Hoffmann JW, Kasper CK, Spitzer SG, Groce SL, Bajaj SP. Single nucleotide primer extension to detect genetic disease: experimental application to hemophilia B (factor IX) and cystic fibrosis genes. *Proc Natl Acad Sci USA* 1991; 88: 1143-7.
  22. Ministry of Health, Labour and Welfare, Japan. The National Nutrition Survey in Japan, 2002. Daiichi-Syuppan: Tokyo, 2004. (in Japanese)
  23. Tsubono Y, Kobayashi M, Sasaki S, Tsugane S. Validity and reproducibility of a self-administered food frequency questionnaire used in the baseline survey of the JPHC Study Cohort I. *J Epidemiol* 2003; 13(1 Suppl): S125-S133.
  24. Ogawa K, Tsubono Y, Nishino Y, Watanabe Y, Ohkubo T, Watanabe T, et al. Validation of a food-frequency questionnaire for cohort studies in rural Japan. *Public Health Nutr* 2003; 6: 147-57.
  25. Poulriot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 1994; 73: 460-8.
  26. Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner AR, et al. A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. *Diabetologia* 1997; 40: 469-72.
  27. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat Med* 1995; 1: 1155-61.
  28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 1993; 259:87-91.
  29. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med* 1996; 2:800-3.
  30. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). *Biochem Biophys Res Commun* 1996; 221:286-9.
  31. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. *Curr Opin Lipidol* 2002; 13: 51-9.
  32. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through cAMP-dependent pathway. *Circulation* 2000; 102: 1296-301.
  33. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood* 2000; 96: 1723-32.
  34. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 2003; 46: 459-69.
  35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285: 2486-97.
  36. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* 2004; 53: 2087-94.
  37. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Arch Intern Med* 2004; 164: 1066-76.

Koichi Miyaki · Mitsuru Murata · Haruhito Kikuchi  
Izumi Takei · Takeo Nakayama · Kiyooki Watanabe  
Kazuyuki Omae

## Assessment of tailor-made prevention of atherosclerosis with folic acid supplementation: randomized, double-blind, placebo-controlled trials in each MTHFR C677T genotype

Received: 17 January 2005 / Accepted: 17 March 2005 / Published online: 14 May 2005  
© The Japan Society of Human Genetics and Springer-Verlag 2005

**Abstract** This study aimed at assessing the effect of folic acid supplementation quantitatively in each MTHFR C677T genotype and considered the efficiency of tailor-made prevention of atherosclerosis. Study design was genotype-stratified, randomized, double-blind, placebo-controlled trials. The setting was a Japanese company in the chemical industry. Subjects were 203 healthy men after exclusion of those who took folic acid or drugs known to effect folic acid metabolism. Intervention was folic acid 1 mg/day p.o. for 3 months. The primary endpoint was plasma total homocysteine level (tHcy). In all three genotypes, there were significant tHcy decreases. The greatest decrease was in the TT homozygote [6.61 (3.47–9.76)  $\mu\text{mol/l}$ ] compared with other genotypes [CC: 2.59 (1.81–3.36), CT: 2.64 (2.16–3.13)], and there was a significant trend between the mutated allele number and the decrease. The tHcy were significantly lowered in all the genotypes, but the amount of the de-

crease differed significantly in each genotype, which was observed at both 1 and 3 months. Using these time-series data, the largest benefit obtained by the TT homozygote was appraised as 2.4 times compared with the CC homozygote. Taking into account the high allele frequency of this SNP, this quantitative assessment should be useful when considering tailor-made prevention of atherosclerosis with folic acid.

**Keywords** Arteriosclerosis · Homocysteine · Folic acid · Dietary supplements · Methylenetetrahydrofolate reductase (NADPH2) · Polymorphism

### Introduction

In 1969, McCully reported the vascular pathology of severe, inherited, homocysteinemia for the first time (McCully 1969). Since then, many studies on hyperhomocysteinemia have been conducted, and elevated plasma total homocysteine (tHcy) level has become an established risk factor for atherosclerotic vascular diseases in many persuasive systematic reviews (Boushey et al. 1995; Welch and Loscalzo 1998; Hankey and Eikelboom 1999). Investigations at a genetic level have also progressed and have revealed not only considerably rare mutations that cause severe inherited homocysteinemia but also common polymorphisms, which moderately elevate the homocysteine level. The latter has attracted particular attention in the field of public health because of its high allele frequency in the general population.

In the metabolic pathway of homocysteine, 5,10-methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20) is one of the key enzymes, as well as methionine synthase and cystathionine beta synthase. In the genes of these enzymes, some single nucleotide polymorphisms (SNPs) have been identified, and many studies are elu-

K. Miyaki (✉) · K. Omae  
Department of Preventive Medicine and Public Health,  
School of Medicine, Keio University,  
35 Shinanomachi, Shinjuku-ku,  
Tokyo 160-8582, Japan  
E-mail: miyaki@sc.itc.keio.ac.jp  
Tel.: +81-3-33531211  
Fax: +81-3-33593686

M. Murata · I. Takei  
Department of Internal Medicine,  
School of Medicine,  
Keio University,  
Tokyo, Japan

M. Murata · H. Kikuchi · I. Takei · K. Watanabe  
Department of Laboratory Medicine,  
School of Medicine, Keio University,  
Tokyo, Japan

T. Nakayama  
Department of Health Informatics,  
Kyoto University School of Public Health,  
Kyoto, Japan